These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35158426)

  • 21. [Predictors of disability in a cohort with neuromyelitis optica spectrum].
    Muñoz NL; Giraldo LM; Zuluaga MI; Yasno D; Bareño-Silva J
    Rev Neurol; 2022 Jun; 74(11):347-352. PubMed ID: 35635360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
    Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
    Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Nakamura Y; Liu Z; Fukumoto S; Shinoda K; Sakoda A; Matsushita T; Hayashida S; Isobe N; Watanabe M; Hiwatashi A; Yamasaki R; Kira JI
    Eur J Neurol; 2020 Jan; 27(1):92-99. PubMed ID: 31304648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.
    Fogarty E; Walsh C; Adams R; McGuigan C; Barry M; Tubridy N
    Mult Scler; 2013 Aug; 19(9):1190-6. PubMed ID: 23401128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort.
    Carnero Contentti E; Eizaguirre MB; López PA; Rojas JI; Tkachuk V; Alonso R
    Mult Scler Relat Disord; 2022 Mar; 59():103647. PubMed ID: 35124305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
    Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.
    Desroziers K; Aballéa S; Maman K; Nazir J; Odeyemi I; Hakimi Z
    Health Qual Life Outcomes; 2013 Nov; 11():200. PubMed ID: 24246044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder.
    Cai LJ; Zhang Q; Zhang Y; Chen HX; Shi ZY; Du Q; Zhou HY
    Mult Scler Relat Disord; 2020 Nov; 46():102515. PubMed ID: 33032051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
    Luo W; Wang X; Kong L; Chen H; Shi Z; Zhou H
    J Neuroimmunol; 2024 Mar; 388():578263. PubMed ID: 38309224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
    Demuth S; Guillaume M; Bourre B; Ciron J; Zephir H; Sirejacob Y; Kerbrat A; Lebrun-Frenay C; Papeix C; Michel L; Laplaud D; Vukusic S; Maillart E; Cohen M; Audoin B; Marignier R; Collongues N;
    J Neuroinflammation; 2022 Mar; 19(1):62. PubMed ID: 35236386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resilience and depression/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Nakazawa K; Noda T; Ichikura K; Okamoto T; Takahashi Y; Yamamura T; Nakagome K
    Mult Scler Relat Disord; 2018 Oct; 25():309-315. PubMed ID: 30176401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.
    Seok JM; Choi M; Cho EB; Lee HL; Kim BJ; Lee KH; Song P; Joo EY; Min JH
    PLoS One; 2017; 12(5):e0177230. PubMed ID: 28542592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.